No abstract available
MeSH terms
-
Cost-Benefit Analysis
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dipeptidyl-Peptidase IV Inhibitors / economics*
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Humans
-
Hypoglycemic Agents / economics*
-
Hypoglycemic Agents / therapeutic use
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents